Healthcare Stocks

Clinical Success Lifts Vera (VERA) Shares, Boosting Fund Returns

by
Graph depicting upward trend in Vera Therapeutics stock price following clinical trial success

“Vera Therapeutics achieves major milestone with positive phase three results for atacicept in IgA nephropathy treatment, propelling share values upward and delivering substantial gains to mutual funds and institutional investors positioned in the biotech sector.” Vera Therapeutics has emerged as a standout performer in the biotech landscape following compelling data from its pivotal phase three … Read more

Scotiabank Notes Bristol-Myers Squibb Company (BMY) as Appealing Investment in 2026

by
Graph illustrating Bristol-Myers Squibb stock valuation and 2026 catalysts

Scotiabank has raised its price target for Bristol-Myers Squibb (BMY) to $60, citing the company’s low valuation and a catalyst-rich year ahead in 2026, driven by advancements in its oncology and immunology pipeline, delayed patent cliffs, and strong financial positioning that positions it for potential outperformance in the pharmaceutical sector. Bristol-Myers Squibb stands out in … Read more